CAPR Stock Overview
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Capricor Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.01 |
| 52 Week High | US$8.22 |
| 52 Week Low | US$2.68 |
| Beta | 4.04 |
| 1 Month Change | -27.18% |
| 3 Month Change | 24.32% |
| 1 Year Change | 21.60% |
| 3 Year Change | 27.81% |
| 5 Year Change | 0.74% |
| Change since IPO | -88.07% |
Recent News & Updates
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet
Apr 19
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
Apr 16Recent updates
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet
Apr 19We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
Apr 16Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues
Feb 03Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?
Dec 13Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
Aug 13A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Nov 03Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03
Aug 10Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth
Feb 01We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth
Oct 14Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result
Sep 25Capricor Therapeutics slumps 9% on $75M stock offering
Jun 21Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
May 16When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?
Mar 13Capricor signs intellectual property license for COVID-19 serology test platform
Feb 01Capricor and Lonza tie up in DMD development
Jan 12Dosing underway in Capricor Therapeutics' mid-stage CAP-1002 study in COVID-19
Nov 24Shareholder Returns
| CAPR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -19.8% | -4.7% | -3.7% |
| 1Y | 21.6% | -2.7% | 20.2% |
Return vs Industry: CAPR exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: CAPR exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| CAPR volatility | |
|---|---|
| CAPR Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CAPR's share price has been volatile over the past 3 months.
Volatility Over Time: CAPR's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 102 | Linda Marbán | www.capricor.com |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases.
Capricor Therapeutics, Inc. Fundamentals Summary
| CAPR fundamental statistics | |
|---|---|
| Market cap | US$157.83m |
| Earnings (TTM) | -US$22.29m |
| Revenue (TTM) | US$25.18m |
6.3x
P/S Ratio-7.1x
P/E RatioIs CAPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAPR income statement (TTM) | |
|---|---|
| Revenue | US$25.18m |
| Cost of Revenue | US$36.45m |
| Gross Profit | -US$11.27m |
| Other Expenses | US$11.02m |
| Earnings | -US$22.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | -44.76% |
| Net Profit Margin | -88.52% |
| Debt/Equity Ratio | 0% |
How did CAPR perform over the long term?
See historical performance and comparison